Consumer Alert: Digitek Heart Failure Medications Recalled - A Serious Risk of Injury or Death to the Patient

May 21, 2008

On April 25, 2008 Actavis Totowa LLC (formerly known as Amide Pharmaceutical, Inc.) announced the Class I nationwide recall of all strengths of oral Digitek tablets, which is a brand name for digoxin tablets, USP 0.125 mg and 0.25 mg.[1]  The products are manufactured by Actavis Totawa LLC, a division of the international generic pharmaceutical company Actavis Group, and distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label.[2]

The Reason Behind the Nationwide Recall:

Digitek is used to treat heart failure and abnormal heart rhythms.[3]  Unfortunately, all lots of the drug have been voluntarily recalled because tablets may be double the appropriate thickness and thus tablets may contain twice the approved level of the active ingredient.[4]  The existence of double-strength tablets poses a risk of toxicity in patients with renal failure and those who are on dialysis.[5] 

How the Recalled Medications Can Injure Patients:

Too high a dosage of Digitek can cause Digitalis toxicity, which can lead to nausea, vomiting, dizziness, low blood pressure, cardiac instability, bradycardia and even death.[6]  The recall was initiated after several reports of injuries and illnesses have been received.[7] 

Attorneys at Robins, Kaplan, Miller & Ciresi L.L.P. are currently investigating claims related to Digitek.  If you or someone you know has been injured or killed following use of Digitek and you wish to consult with a lawyer, please call Kate Jaycox at 1-800-553-9910 or 612-349-8500 or e-mail us by clicking on this link: contact us

[1] Press Releases, Digitek Recall - Customer Support and Frequently Asked Questions, dated May 9, 2008
[2] Press Releases, Actavis Totowa (formerly known as Amide Pharmaceutical, Inc.) recalls all lots of Bertek and UDL Laboratories Digitek (digoxin tablets, USP) as a precaution, dated April 25, 2008, available at or at Recall - - Firm Press Release, 
[3] Id. 
[4] Id. 
[5] Id. 
[6] Id. 
[7] Id.

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.


Related Publications

Fall 2021
Are All Fiduciaries Created Equal?
Erica Ramsey - The Robins Kaplan Spotlight, Vol. 6, No. 3
Fall 2021
Context Matters: Fiduciaries and the Rule Against Self-Dealing
Brendan Johnson, Tim Billion - The Robins Kaplan Spotlight, Vol. 6, No. 3
Fall 2021
Update on DOL Fiduciary Rule
Michael Reif - The Robins Kaplan Spotlight, Vol. 6, No. 3
September 28, 2021
Briefly: Federal appeals: How much notice is enough?
Stephen Safranski and Geoffrey Kozen - Minnesota Lawyer
Summer 2021
IATL President's Letter on Judicial Security
Roman Silberfeld - The Robins Kaplan Quarterly: Tackling Tough Business Litigation Matters
Back to Top